Targeted Therapies Compared to Dacarbazine for Treatment of BRAF^V600E Metastatic Melanoma: A Cost-Effectiveness Analysis

Table 2

Cost-effectiveness of dabrafenib relative to dacarbazine and vemurafenib relative to dabrafenib.

	Total cost	Total effectiveness	Incremental cost	Incremental effectiveness	ICER
Dacarbazine	$15,221	0.1820 QALYs
Dabrafenib	$38,547	0.3385 QALYs	$23,325	0.1565 QALYs	$149,042
Vemurafenib	$49,938	0.2905 QALYs	Dominated	Dominated	Dominated

QALYs: quality-adjusted life years; ICER: incremental cost-effectiveness ratio.
Note: comparisons are to the next least costly alternative.